Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Time-of-day of first checkpoint inhibitor dose influences clinical outcomes and immune responses in hepatocellular carcinoma.
Journal: Journal for immunotherapy of cancer
Published: February 02, 2026
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.
Journal: Cancer immunology research
Published: December 17, 2025
Profiling ADC targets in cholangiocarcinoma: implications for therapeutic development.
Journal: NPJ precision oncology
Published: July 18, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy.
Journal: Cancer research communications
Published: May 05, 2025
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.
Journal: The Journal of clinical investigation
Published: March 17, 2025
A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial.
Journal: Nature medicine
Published: February 19, 2025
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines.
Journal: Cancer immunology research
Published: October 24, 2024
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade.
Journal: Journal for immunotherapy of cancer
Published: October 07, 2024
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors.
Journal: Nature communications
Published: May 14, 2024
Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC.
Journal: Cancer research communications
Published: March 11, 2024
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.
Journal: Cancer research communications
Published: February 05, 2024
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.
Journal: The Journal of clinical investigation
Published: November 20, 2023
Last Updated: 09/26/2026